Dr Roberto Solari: Ledger

Stories naming Dr Roberto Solari. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Venture Partner	Brandon Capital	Forbes Australia, Brandon BioCatalyst

2 deals

Brandon Capital scores its biggest return ever with $2.1bn biotech acquisition

Novartis is acquiring London biotech Myricx Bio for US$1.1 billion upfront plus milestone payments, handing Melbourne venture firm Brandon Capital a record return on the startup it seeded in 2019.

Forbes Australia 7 Jul 2026 Myricx Bio Novartis QIC Ventures Aware Super Brandon Capital CSL HEST A Hostplus Mohit Rawat Dr Roberto Solari Dr Stephen Thompson

Grant $18.9m

ENA Respiratory: The Difference Between Chance and Discovery? Knowing What to Do Next.

A profile of ENA Respiratory traces its INNA-051 immune-boosting nasal spray from an accidental lab finding to Phase 2 trials, noting AUD 49 million in funding, a US Defence contract and Flu Lab investment.

Brandon BioCatalyst portfolio 7 Apr 2025 ENA Respiratory Brandon Capital Flu Lab GSK U.S. Department of Defense Dr Chris Smith Christophe Demaison Dr Roberto Solari

Dr Roberto Solari

Roles

Coverage

Brandon Capital scores its biggest return ever with $2.1bn biotech acquisition

ENA Respiratory: The Difference Between Chance and Discovery? Knowing What to Do Next.